Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris

NCT ID: NCT00750152

Last Updated: 2013-04-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 334 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-30
• Study Completion Date: 2010-02-28

Brief Summary

A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.

Detailed Description

To evaluate the efficacy and safety of NAFT-500, applied once daily for 2 weeks, compared to placebo in the treatment of subjects with potassium hydroxide (KOH) and culture positive symptomatic tinea cruris.

Conditions

Tinea Cruris; Jock Itch

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

2

placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

placebo cream applied for up to 4 weeks

1

NAFT-500

Group Type: EXPERIMENTAL

NAFT-500

Intervention Type: DRUG

topical cream application up to 4 weeks

Interventions

NAFT-500

topical cream application up to 4 weeks

Intervention Type: DRUG

Placebo

placebo cream applied for up to 4 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Review and sign a statement of Informed Consent and HIPAA authorization.

2. Males or non-pregnant females ≥12 years of age, of any race or sex. Females of childbearing potential must have a negative urine pregnancy test.

3. For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).

4. Presence of tinea cruris characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) as confirmed by signs and symptoms.

5. KOH positive and culture positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.

6. Subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations.

7. Subjects must be able to understand the requirements of the study and willing to comply with the study requirements.

Exclusion Criteria

1. A life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.

2. Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.

3. Subjects with a known hypersensitivity to study medications or their components.

4. Subjects who have a recent history or who are currently known to abuse alcohol or drugs.

5. Uncontrolled diabetes mellitus.

6. Hemodialysis or chronic ambulatory peritoneal dialysis therapy.

7. Current diagnosis of immunocompromising conditions.

8. Atopic or contact dermatitis.

9. Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.

10. Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized or post menopausal for at least 2 years are not considered to be of childbearing potential). For the purposes of this study,acceptable forms of birth control include: oral contraceptives, contraceptive patches/implants, double barrier methods (e.g., use of condom and spermicide), IUD, and abstinence with second acceptable method should subject become sexually active.

11. Subjects using the following medications:

• Topical anti-fungal therapy, powders or topical corticosteroids applied within 14 days prior to randomization. Terbinafine, butenafine, and naftifine (topical) within 30 days prior to randomization.
• Oral anti-fungal therapies within 3 months of randomization (8 months for oral terbinafine).
• Systemic antibiotic or corticosteroid treatment within 30 days of randomization.
• Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.
• Investigational drug/ device within 30 days of randomization

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Merz North America, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lawrence Parish, MD

Role: PRINCIPAL_INVESTIGATOR

Paddington Testing Company

Locations

Radiant Research

Birmingham, Alabama, United States

University Clinical Trials

San Diego, California, United States

University of California San Francisco Dept of Dermatology

San Francisco, California, United States

FXM Research

Miami, Florida, United States

FXM Research

Miramar, Florida, United States

Tulane Univeristy Health Services Ctr.

New Orleans, Louisiana, United States

Silverton Skin Institute

Grand Blanc, Michigan, United States

Zoe Draelos, MD

High Point, North Carolina, United States

Haber Dermatology

Euclid, Ohio, United States

Paddington Testing Company

Philadelphia, Pennsylvania, United States

Tennesse Clinical Research

Nashville, Tennessee, United States

J&S Studies

College Station, Texas, United States

Research Across America

Dallas, Texas, United States

Research Across America

Plano, Texas, United States

Oakwell Clinical Research

San Antonio, Texas, United States

Edwin Camilio Vazquez, MD

Aguas Buenas, , Puerto Rico

Medicina General y Cirugia Menor

Cayey, , Puerto Rico

Advanced Medical Concepts, PSC

Cidra, , Puerto Rico

Manuel Guzman, MD

Humacao, , Puerto Rico

Isabel Quijano, MD

Rio Piedras, , Puerto Rico

Countries

United States; Puerto Rico

References

Parish LC, Parish JL, Routh HB, Avakian E, Olayinka B, Pappert EJ, Plaum S, Fleischer AB, Hardas B. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. 2011 Oct;10(10):1142-7.

Reference Type: RESULT

PMID: 21968664 (View on PubMed)

Related Links

http://dailymed.nlm.nih.gov/

Naftin Cream 2% product information

Other Identifiers

MRZ 90200/FI/3001

Identifier Type: -

Identifier Source: org_study_id